Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G TopicsReproductive endocrinology & infertility

O&G · Reproductive endocrinology & infertility

Hyperprolactinaemia: prolactinoma diagnosis (macroprolactin, MRI pituitary), cabergoline management, pregnancy considerations

Also known as Hyperprolactinemia · Elevated prolactin · Prolactinoma · Pituitary adenoma prolactin-secreting · Macroprolactinaemia · Cabergoline · Dopamine agonist · Galactorrhoea workup

Exam-exhaustive FRANZCOG fellowship topic on hyperprolactinaemia. Walks the clinical presentation (oligomenorrhoea, galactorrhoea, hypogonadism, visual symptoms with macroprolactinoma), the investigation ladder (pregnancy exclusion, prolactin with macroprolactin interference, TFT, MRI pituitary with gadolinium), the classification (micro- vs macro-adenoma 10 mm threshold, stalk effect versus true secretion), the management (cabergoline preferred over bromocriptine, dose titration, dopamine agonist withdrawal criteria), and pregnancy considerations (visual field monitoring, dopamine agonist safety, breastfeeding). Hyperprolactinaemia is a common cause of secondary amenorrhoea and sits in the Pituitary arm of the FIGO HyPO-P (hypothalamic, pituitary, ovarian, PCOS) classification; this topic covers the workup and management end to end.

high11 referencesUpdated 5 Sept 202625 min readSource-verified · Sept 2026

Checked against its sources on 12 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI

Red flags

  • Acute severe headache with visual loss, ophthalmoplegia, and altered consciousness in a known or new pituitary adenoma — pituitary apoplexy; urgent MRI, hydrocortisone 100 to 200 mg IV bolus before imaging, neurosurgical decompression if vision or neurology deteriorates
  • Bitemporal hemianopia on confrontation with secondary amenorrhoea and a prolactin over 250 micrograms per litre — macroprolactinoma with chiasmal compression; start cabergoline urgently, arrange pituitary surgery input, urgent MRI with gadolinium
  • Pregnant woman with a known macroprolactinoma — monthly clinical review with visual field evaluation every 3 months; MRI pituitary without gadolinium if growth suspected; maintenance dopamine agonist therapy is an option for large macroprolactinomas; do not stop dopamine agonist without review
  • Pituitary mass with a disproportionately low prolactin for its size (under the 200 ng/mL prolactinoma threshold) — likely stalk effect from a non-functioning adenoma, NOT a true prolactinoma; treatment is surgery, NOT escalating dopamine agonist (which would mask tumour growth)
  • Patient on an antipsychotic (risperidone, amisulpride, haloperidol) with new amenorrhoea and galactorrhoea — drug-induced hyperprolactinaemia; review with psychiatry before imaging; consider switching to a prolactin-sparing agent (aripiprazole is the consensus-named choice)
  • Hyperprolactinaemia in pregnancy with new visual symptoms — do NOT assume physiological; MRI without gadolinium; consider delivery if vision threatened
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI

Red flags

  • Acute severe headache with visual loss, ophthalmoplegia, and altered consciousness in a known or new pituitary adenoma — pituitary apoplexy; urgent MRI, hydrocortisone 100 to 200 mg IV bolus before imaging, neurosurgical decompression if vision or neurology deteriorates
  • Bitemporal hemianopia on confrontation with secondary amenorrhoea and a prolactin over 250 micrograms per litre — macroprolactinoma with chiasmal compression; start cabergoline urgently, arrange pituitary surgery input, urgent MRI with gadolinium
  • Pregnant woman with a known macroprolactinoma — monthly clinical review with visual field evaluation every 3 months; MRI pituitary without gadolinium if growth suspected; maintenance dopamine agonist therapy is an option for large macroprolactinomas; do not stop dopamine agonist without review
  • Pituitary mass with a disproportionately low prolactin for its size (under the 200 ng/mL prolactinoma threshold) — likely stalk effect from a non-functioning adenoma, NOT a true prolactinoma; treatment is surgery, NOT escalating dopamine agonist (which would mask tumour growth)
  • Patient on an antipsychotic (risperidone, amisulpride, haloperidol) with new amenorrhoea and galactorrhoea — drug-induced hyperprolactinaemia; review with psychiatry before imaging; consider switching to a prolactin-sparing agent (aripiprazole is the consensus-named choice)
  • Hyperprolactinaemia in pregnancy with new visual symptoms — do NOT assume physiological; MRI without gadolinium; consider delivery if vision threatened
One-line fellowship answer

Hyperprolactinaemia presents with oligomenorrhoea or amenorrhoea, galactorrhoea, hypogonadism, infertility, and (with macroprolactinoma) bitemporal hemianopia. The workup is β-hCG → TSH → prolactin (with macroprolactin screen by polyethylene glycol precipitation when the level is under 200 ng/mL and the picture is discordant) → MRI pituitary with gadolinium for confirmed hyperprolactinaemia once other causes are excluded, and urgently for headaches or visual symptoms. The key distinction is true prolactinoma (prolactin proportional to tumour size; over 250 micrograms per litre usually indicates a prolactinoma, over 500 is diagnostic of macroprolactinoma) from stalk effect (modest prolactin elevation despite a large mass — under the 200 ng/mL level at which a prolactinoma becomes more probable). Cabergoline first-line (start low, 0.25 mg twice weekly, titrate stepwise; commonly 0.5 to 3.5 mg weekly); dopamine agonist withdrawal may be considered after at least 2 years of treatment with normoprolactinaemia and substantial tumour shrinkage (recurrence 26 to 69% unselected; about 45% of microprolactinomas recur even in well-selected patients). In pregnancy, microprolactinomas are usually observed (symptomatic growth 2.6%); macroprolactinomas need monthly clinical review with visual fields every 3 months and continuation of dopamine agonist if they are large or abut the chiasm.

[1]

A 28-year-old teacher presents with three months of secondary amenorrhoea, intermittent galactorrhoea she had not mentioned until asked, and decreased libido. Her medication list includes risperidone for bipolar disorder. A 42-year-old man presents with headaches, bitemporal hemianopia, erectile dysfunction, and a prolactin of 4,200 micrograms per litre. A 36-year-old woman with a known microprolactinoma on cabergoline 0.5 mg twice weekly is now 8 weeks pregnant and asks whether to stop the medication. None of these is the same problem, but each test of management is the same principle — confirm the prolactin is real, identify the mechanism, choose cabergoline first-line, and tailor the dose to the patient.[1][3]

Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References11ShowHide
  1. [1]Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011.PMID 21296991
  2. [2]Oğuz O, Palaoğlu KE, Incir S. Prevalence and re-evaluation of macroprolactinemia in hyperprolactinemic patients: a retrospective study in the Turkish population. Clin Chem Lab Med, 2025.PMID 40183492
  3. [3]Puzio A, Hylinska M, Kapała O, et al. Beyond normalization: rethinking optimal prolactin levels in prolactinoma management. Expert Rev Endocrinol Metab, 2026.PMID 42191233
  4. [4]Cai X, Zhu J, Yang J, et al. Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. Chin Neurosurg J, 2022.PMID 35395837
  5. [6]Otis AS, Brochet MS, Tremblay Z, et al. Cabergoline Use and Pregnancy Outcomes: A Systematic Review. Birth Defects Res, 2025.PMID 40116053
  6. [7]Giri S, Suryadevara V, Ramesh AS, et al. The Spectrum of Serum Prolactin Levels in Patients with Non-Functioning Sellar Masses: A Retrospective Analysis. Neurol India, 2026.PMID 41817061
  7. [8]Sakata K, Hashimoto A, Takeshige N, et al. Clinical and radiographic characteristics of patients with non-functioning pituitary adenomas categorized according to their serum prolactin levels. Endocrine, 2024.PMID 38664336
  8. [9]Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol, 2023.PMID 37670148
  9. [12]Balen AH, Tamblyn J, Skorupskaite K, Munro MG A comprehensive review of the new FIGO classification of ovulatory disorders. Hum Reprod Update, 2024.PMID 38412452
  10. [16]Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf), 2006.PMID 16886971
  11. [15]Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf), 2011.PMID 21044119

Test yourself

Practise what you just read

  • 8 MCQs
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousFertility preservation (oncofertility, oocyte, embryo and ovarian tissue cryopreservation)Reproductive endocrinology & infertilityNextInfertility: assessment & investigation — NICE NG257 (2026), WHO 6th-edition semen criteria, and the structured couple workupReproductive endocrinology & infertility